UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
Date of Report: For the month of May 2013
Commission File No.: 001-35773
REDHILL BIOPHARMA LTD.
(Translation of registrant’s name into English)
21 Ha'arba'a Street, Tel Aviv, 64739, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F S Form 40-F £
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
During the upcoming BioTrinity 2013 European Biopartnering and Investment Conference, which will take place in Newbury, Berkshire, UK, on May 14-16, 2013, the Company expects to meet with individuals from the pharmaceutical industry and provide them with a presentation regarding the Company. A copy of the presentation to be provided by the Company has been uploaded to the Company's website and may be viewed at the following web address: http://ir.redhillbio.com/events.cfm.
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | REDHILL BIOPHARMA LTD. |
| | (the "Registrant") |
| | |
Date: May 13th, 2013 | By: /s/ Dror Ben-Asher |
| | —————————————— |
| | Dror Ben-Asher |
| | Chief Executive Officer |
